Lantheus to Present at the UBS Global Healthcare Conference
NORTH BILLERICA, Mass., May 10, 2022 – Lantheus Holdings (NASDAQ: LNTH) announced that President and CEO Mary Anne Heino, along with CFO Bob Marshall, will present at the UBS Global Healthcare Conference. The presentation is scheduled for 8:30 a.m. ET on May 24, 2022, in New York. Investors can access a live webcast through the Company’s website, with a replay available for 30 days post-event. Lantheus is known for its innovative imaging diagnostics and AI solutions aimed at serious medical conditions.
- None.
- None.
NORTH BILLERICA, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced Mary Anne Heino, President and Chief Executive Officer, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the UBS Global Healthcare Conference at 8:30 a.m. ET on Tuesday, May 24, in New York.
To access a live webcast of the presentation, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcast will be available on the Company’s website for 30 days following the live presentation.
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow® serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; PYLARIFY AI™, an artificial intelligence platform that assists in the evaluation of PSMA PET images; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New Jersey, Canada and Sweden. For more information, visit www.lantheus.com.
Contacts:
Mark Kinarney
Senior Director, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Senior Director, Corporate Communications
646-975-2533
media@lantheus.com
FAQ
When will Lantheus Holdings present at the UBS Global Healthcare Conference?
Who will represent Lantheus Holdings at the UBS Global Healthcare Conference?
How can I watch the Lantheus Holdings presentation at the UBS Global Healthcare Conference?
Is there a replay available for the Lantheus Holdings presentation?
